Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week DHEA and sustained-release melatonin for sleep and menopausal symptoms in postmenopausal women
2022-004160-16Phase 3Active
- Sponsor
- Lek-AM
- Start
- Nov 2023
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sleep disorder, menopause and affective disorder comparing DHEA 20 mg + sustained-release melatonin 2 mg with Placebo (2 arms). Primary endpoints: Sleep quality improvement after 12 weeks, Mood improvement after 12 weeks and 1 more. Started Nov 2023; status: active.
02
Drugs
dehydroepiandrosteronemelatonin
03
Conditions
sleep disordermenopauseaffective disorder
Beyond the preview
Go deeper on 2022-004160-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004160-16.